Top Page
Max Healthcare Institute Ltd
(MAXHEALTH)
Max Healthcare Institute Ltd (MAXHEALTH) vs. iShares MSCI India ETF (INDA)
Max Healthcare Institute Ltd Business Overview & Revenue Model
Max Healthcare Institute Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 75.13B | 70.28B | 54.06B | 45.63B | 39.37B | 25.08B |
| Gross Profit | 46.75B | 43.77B | 33.53B | 28.31B | 21.89B | 12.76B |
| EBITDA | 19.09B | 18.31B | 14.82B | 12.23B | 9.47B | 3.90B |
| Net Income | 11.48B | 10.76B | 10.58B | 11.04B | 6.05B | -1.38B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 152.14B | 120.00B | 101.02B | 91.89B | 85.44B |
| Cash, Cash Equivalents and Short-Term Investments | 6.62B | 6.82B | 9.80B | 13.74B | 4.81B | 6.27B |
| Total Debt | 0.00 | 30.10B | 13.05B | 6.89B | 11.33B | 13.25B |
| Total Liabilities | -93.81B | 58.34B | 35.92B | 26.92B | 29.07B | 29.06B |
| Stockholders Equity | 93.81B | 93.81B | 84.08B | 74.10B | 62.82B | 56.39B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 4.94B | 3.36B | 8.74B | 1.87B | -5.60M |
| Operating Cash Flow | 0.00 | 14.59B | 11.22B | 12.09B | 7.48B | 1.18B |
| Investing Cash Flow | 0.00 | -16.32B | -12.85B | -11.87B | -7.72B | -730.00M |
| Financing Cash Flow | 0.00 | -1.64B | -2.64B | -2.89B | -2.94B | 1.91B |
Max Healthcare Institute Ltd Technical Analysis
Max Healthcare Institute Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹361.28B | 42.54 | ― | 0.24% | 14.72% | 8.37% | |
66 Neutral | ₹931.21B | 68.56 | ― | 0.14% | 32.17% | 28.12% | |
66 Neutral | ₹1.00T | 59.86 | ― | 0.27% | 13.66% | 41.32% | |
65 Neutral | ₹241.54B | 71.89 | ― | ― | 25.74% | 1.41% | |
65 Neutral | ₹283.59B | 50.46 | ― | 0.04% | 15.78% | 15.01% | |
61 Neutral | ₹642.96B | 63.41 | ― | 0.11% | 15.33% | 54.62% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Max Healthcare Institute Ltd Corporate Events
Max Healthcare Institute Ltd has disclosed that it has received an order from the Office of the GST Officer, Department of Trade and Taxes, Government of NCT of Delhi, alleging excess availment of input tax credit. The order raises a GST demand of ₹33.66 crore, along with interest of ₹18.18 crore and a penalty of ₹3.37 crore, potentially exposing the company to a material tax liability. Management is seeking rectification of the order and, if the outcome is unfavourable, may appeal before the appropriate authority, indicating that the final financial impact and timeline of resolution remain uncertain for shareholders and other stakeholders.
Max Healthcare Institute Ltd has disclosed that it has received a Goods and Services Tax (GST) order from the Office of the Principal Commissioner of Central GST, Delhi South Commissionerate, raising a demand of ₹6.36 crore along with applicable interest and an equivalent amount as penalty. The order stems from alleged discrepancies related to Goods and Services Tax provisions involving input tax credit and tax recovery, though the company has stated that the financial impact is limited to the demanded amount and that there will be no material effect on its operational or other activities; management has initiated the process of filing an appeal against the order, signaling its intent to contest the tax demand.
Max Healthcare Institute Ltd has been assigned an ESG rating of ’66’ for the financial year 2024-25 by NSE Sustainability Ratings and Analytics Limited, reflecting an improvement from the previous year’s rating of ’62’. This independent assessment, based on public disclosures, highlights the company’s enhanced commitment to environmental, social, and governance standards, potentially strengthening its position in the healthcare industry and providing positive implications for stakeholders.
Max Healthcare Institute Ltd has reported strong financial performance for the second quarter and first half of FY’26, with a 21% year-on-year revenue growth and a 23% increase in operating EBITDA. This marks the 20th consecutive quarter of growth, driven by the strength of its core operations and strategic expansions, such as the new 160-bed addition at Max Mohali. The company’s consistent growth and expansion efforts underscore its robust market positioning and commitment to enhancing healthcare services.
Max Healthcare Institute Ltd has announced that the audio recording of its earnings call, held on November 17, 2025, is now accessible on its website. This announcement pertains to the financial results for the quarter and half-year ending September 30, 2025, and provides stakeholders with insights into the company’s financial performance and strategic direction.
Max Healthcare Institute Ltd has announced its participation in upcoming investor conferences, including the CLSA India Forum and the Goldman Sachs India CIO Tour. These events will feature presentations by the company’s Chairman, Managing Director, and Senior Management, highlighting the company’s strategic initiatives and market positioning.
Max Healthcare Institute Ltd has released its financial results for the quarter and half-year ended September 30, 2025, showing a significant increase in revenue and profit compared to the previous year. The company reported consolidated revenue from operations of ₹213,547 lakhs for the quarter, with a profit after tax of ₹49,130 lakhs. A notable development is the merger of its subsidiaries, Crosslay Remedies Limited and Jaypee Healthcare Limited, approved by the NCLT, which resulted in tax benefits. Additionally, the company divested two hospitals in line with its strategic focus on larger cities, and a final dividend was approved and paid to shareholders.
Max Healthcare Institute Ltd. reported significant financial growth for the second quarter of 2025, with a 21% year-over-year increase in revenue to ₹2,692 crore and a 23% rise in Network Operating EBITDA to ₹694 crore. The company’s profit after tax surged by 59% to ₹554 crore, partly due to a favorable tax impact from the merger of its subsidiaries. The quarter also saw increased bed occupancy and international patient revenue, alongside strategic expansions with new facilities being commissioned. These developments underscore Max Healthcare’s strengthened market position and operational efficiency, benefiting stakeholders through enhanced service capabilities and financial performance.
Max Healthcare Institute Ltd. reported significant financial growth for the quarter ended September 30, 2025, with a 21% year-over-year increase in gross revenue to ₹2,692 crore, driven by a rise in occupied bed days and international patient revenue. The company’s operating EBITDA grew by 23% year-over-year to ₹694 crore, with a network PAT growth of 59% to ₹554 crore, partially due to a favorable tax impact from the merger of two subsidiaries. The company also announced the commissioning of new healthcare facilities and the divestment of certain hospital assets, which are expected to enhance its operational capacity and market positioning.
Max Healthcare Institute Ltd has announced the approval of 280,308 stock options granted to eligible employees under its Employee Stock Option Scheme 2022. This move, approved by the Nomination and Remuneration Committee, is part of the company’s efforts to incentivize and retain talent, potentially impacting employee satisfaction and aligning interests with company growth.
Max Healthcare Institute Ltd has announced the approval of a Scheme of Amalgamation between its wholly owned subsidiaries, Crosslay Remedies Limited and Jaypee Healthcare Limited. The National Company Law Tribunal, Chandigarh Bench, has sanctioned the merger, which is set to have an appointed date of October 5, 2024. This strategic move is expected to streamline operations and enhance the company’s market positioning, potentially benefiting stakeholders by creating a more unified and efficient healthcare service provider.